ClinicalTrials.gg
CompletedNCT01563445Updated Jan 13, 2017

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

A Phase 2 interventional study of activated recombinant human factor VII and placebo in Acquired Bleeding Disorder and Intracerebral Haemorrhage, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-13.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage — 1 open to participants now, 2 under way, 2 of them phase 3. recombinant FVIIa · Cerebral Hemorrhage.

Enrollment
9th of 11
40 · median 90
Started
2001
with 1 other
Phase 2
8 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
5 of 11
Novo Nordisk A/S

Among the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, this one is the 9th largest by enrollment, is one of 2 that started in 2001, is one of 8 in phase 2, and was the 8th registered.

Cerebral Hemorrhage

457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

1 of the 11 studies testing recombinant FVIIa in Cerebral Hemorrhage is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Cerebral Hemorrhage studies recruiting now, 59 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing recombinant FVIIa in Cerebral Hemorrhage, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).

03

Conditions studied

  • Acquired Bleeding Disorder
  • Intracerebral Haemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spontaneous ICH diagnosed by CT (Computerized Tomography) scanning within 3 hours of onset
  • Signed form, or an exception from standard informed consent requirements

Exclusion criteria

Exclusion Criteria:

  • Time of onset of symptoms of ICH unknown or more than 3 hours prior to CT
  • Patients with secondary ICH related to infarction, hemophilia or other coagulopathy, tumor, trauma, haemorrhagic infarction, cerebrovenous thrombosis, aneurysm, AVM (Arteriovenous Malformation) or severe trauma
  • Surgical haematoma evacuation planned or performed within 24 hours of onset
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    activated recombinant human factor VII

    Drug: activated recombinant human factor VII

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult

  • Drugplacebo

    Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult

06

What researchers measure

Primary outcomes

  1. Occurrence of a treatment-related serious adverse event (SAE)

Secondary outcomes

  1. Occurrence of adverse events

  2. Change in ICH volume as measured by CT head scans

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    New York, New York 10032, United States
08

References and documents

Publications

  • Mayer SA, Brun NC, Broderick J, Diringer MN, Davis SM, Steiner T. Safety and Preliminary Efficacy of Recombinant Coagulation Factor VII in Patients with Acute Intracerebral Hemorrhage. Stroke 2004; 35: 322
  • Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke. 2008 Mar;39(3):850-6. doi: 10.1161/STROKEAHA.107.493601. Epub 2008 Jan 31. PubMed 18239180 ↗
  • Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, Steiner T; United States NovoSeven ICH Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care. 2006;4(3):206-14. doi: 10.1385/NCC:4:3:206. PubMed 16757825 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Mar 2003 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2012
First posted
Mar 27, 2012
Start
Nov 2001
Primary completionActual
Mar 2003
CompletionActual
Mar 2003
Last update
Jan 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01563445
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 27, 2012
Start date
Nov 2001
Primary completion
Mar 2003
Completion
Mar 2003
Last update
Jan 13, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion